Obesity Drug Approvals Foretell A Less Cautious FDA

Law360, New York (July 19, 2012, 9:23 PM EDT) -- The U.S. Food and Drug Administration's approval of two weight-loss drugs in less than a month — 13 years after the last such approval — signals that the FDA is willing to tolerate more risk, after years of what industry critics say was an over-cautious approach that kept good drugs off the market.

On Tuesday, the FDA approved Vivus Inc.'s Qsymia, about three weeks after approving Belviq, a drug made by Arena Pharmaceuticals GmbH. Both drugs, which work in different ways to suppress hunger, are approved...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.